There continues to be rapid advancement in the understanding of pathogenesis of immune mediated kidney disease. This progress has culminated into development of multiple therapeutic agents that have consistently improved renal and patient outcomes. The focus of this review is to discuss these recent advancements in immune mediated kidney disease via the lens of direct and indirect immune mediated mechanisms. In the direct immune mediated disease, recently described antigens in anti-GBM disease and membranous nephropathy are discussed, along with new therapeutic regimes in membranous nephropathy and focal segmental glomerulosclerosis. From an indirect immune disease standpoint, recent pivotal trials in anti-neutrophil cytoplasmic antibody vasculitis, lupus nephritis and IgA nephropathy are examined from a real world practice perspective. New molecular pathways in various disorders of alternate complement pathway are described, which in turn, have led to development of various experimental therapies. In addition, pivotal and ongoing therapeutic trials in the aforementioned diseases are presented.Copyright © 2021. Published by Elsevier Inc.
About The Expert